Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Treasury Shares (2019 - 2025)

Historic Treasury Shares for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $16.6 million.

  • Allogene Therapeutics' Treasury Shares rose 2528.83% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year increase of 2528.83%. This contributed to the annual value of $13.3 million for FY2024, which is 955.07% up from last year.
  • Latest data reveals that Allogene Therapeutics reported Treasury Shares of $16.6 million as of Q3 2025, which was up 2528.83% from $17.2 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Treasury Shares ranged from a high of $18.1 million in Q1 2025 and a low of $3.1 million during Q1 2021
  • Over the past 5 years, Allogene Therapeutics' median Treasury Shares value was $12.2 million (recorded in 2023), while the average stood at $10.2 million.
  • Per our database at Business Quant, Allogene Therapeutics' Treasury Shares surged by 14650.05% in 2023 and then increased by 16.13% in 2024.
  • Allogene Therapeutics' Treasury Shares (Quarter) stood at $4.3 million in 2021, then grew by 28.92% to $5.5 million in 2022, then skyrocketed by 121.73% to $12.2 million in 2023, then increased by 9.55% to $13.3 million in 2024, then increased by 24.65% to $16.6 million in 2025.
  • Its Treasury Shares was $16.6 million in Q3 2025, compared to $17.2 million in Q2 2025 and $18.1 million in Q1 2025.